// App-Quantinova.ai

SAT0321 (2018) : Ixekizumab treatment significantly improves enthesitis and dactylitis in patients with active psoriatic arthritis: results from the spirit trials

Researchers

Presenter

  • D.D. Gladman

Principal Investigators

  • A.-M. Orbai

  • G. Gallo

  • J. Birt

  • S. Rathmann

  • H. Marzo-Ortega

Medical Centers

  • University of Toronto, Toronto, ON, Canada

  • Johns Hopkins University, Baltimore, MD

  • Eli Lilly and Company, Indianapolis, IN

  • IHR LBRC, LTHT and LIRMM, University of Leeds, Leeds, UK

Locations

  • Canada

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • NCT01695239

  • NCT02349295

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved